Ligand Set For Partnership Opportunities After Completing On Pfenex

Sets Out Strategy And Revenue Drivers After Finalizing $500m Deal

Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.

Open doors
The Pfenex deal opens the door to at least three new partnerships in the next 12 months, Ligand says • Source: Shutterstock

Ligand Pharmaceuticals expects to strike at least three new partnership deals over the coming year thanks to its acquisition of Pfenex, which the biopharma company has just completed.

Specializing in “developing or acquiring technologies that help pharmaceutical companies discover and develop medicines,” Ligand earlier this year struck a...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business